Date: November 12, 2026

Board Meeting Outcomes

  • The Board of Directors at their meeting held on November 6, 2026, approved a buyback of fully paid-up equity shares.
  • The buyback will be conducted from shareholders/beneficial owners other than promoters and persons in control of the company.
  • The buyback will be executed through the open market route using the stock exchange mechanism.

Buyback Details

  • Maximum Buyback Price: ₹750 per equity share (face value ₹2 each)
  • Maximum Buyback Size: ₹130,00,00,000 (One Hundred and Thirty Crores)
  • Transaction Costs: Excludes brokerage, turnover charges, applicable taxes (STT, GST, stamp duty), filing fees, advisor fees, intermediary fees, public announcement, publication expenses, printing, dispatch and other incidental expenses.

Proposed Schedule of Activities

  • Date of Board resolution approving Buyback: Friday, November 6, 2026
  • Date of publication of Public Announcement: Tuesday, November 10, 2026
  • Date of opening of Buyback: Friday, November 13, 2026
  • Last Date for completion of Buyback: The earlier of:
  • Tuesday, February 16, 2027 (within 66 working days from opening)
  • When company completes buyback by deploying amount equivalent to Maximum Buyback Size
  • At such earlier date determined by the Board after giving notice, subject to deploying Minimum Buyback Size
  • Acceptance of Equity Shares: Upon relevant pay-out by Stock Exchanges
  • Extinguishment of Equity Shares: Equity shares in dematerialized form will be extinguished within 7 working days of expiry of Buyback period as per SEBI regulations.

Additional Information

  • The Public Announcement dated November 9, 2026, is available on company website (www.medplusindia.com), SEBI website (www.sebi.gov.in), NSE website (www.nseindia.com), BSE website (www.bseindia.com) and manager's website (www.nuvama.com).
  • The communication has been sent to shareholders via email where email IDs are available.